ClinicalTrials.gg
CompletedNCT03018366Updated Mar 13, 2025Results posted

Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women

A Phase 2 interventional study of 17beta Estradiol and Transdermal placebo patch in Estrogen Deficiency, Cardiovascular Disease (CVD) and Functional Hypothalamic Amenorrhea, sponsored by Cedars-Sinai Medical Center. Completed at 1 site in United States. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Cedars-Sinai Medical Center · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Study summary

The purpose of this study is to determine whether young women with functional hypothalamic amenorrhea (premenopausal HypoE) is associated with risk factors for pre-clinical cardiovascular disease (CVD).

For this study, the investigators will measuring vascular function and inflammatory markers on:

  • young women with functional hypothalamic amenorrhea (>3 months of no menstrual cycle due to low estrogen)
  • young women with regular menstrual cycles not on hormone therapy.
  • recently menopausal women (\<3 years from final menstrual period) not on hormone therapy.

Premenopausal HypoE participants (women with functional hypothalamic amenorrhea) will be randomized to use either an estrogen patch or a placebo patch (no active medicine) for 12 weeks, followed by estrogen or placebo patch plus progesterone or placebo pills for 2 additional weeks. The investigators are looking to see if estrogen improves vascular and inflammation.

Read the detailed description

Study Aims:

  1. To test the hypothesis premenopausal HypoE (women with FHA) is associated with pre-clinical CVD as determined by reductions in vascular endothelial function.
  2. To test the hypothesis premenopausal HypoE (women with FHA) is associated with increased immune-mediated inflammation.
  3. To test the hypothesis whether estrogen replacement can reduce inflammation and improve vascular endothelial function in premenopausal HypoE women (women with FHA).

In a randomized, double-blind placebo-controlled trial in premenopausal HypoE women (women with FHA) the investigators will test 12 weeks of transdermal estradiol 0.1 mg/day patch or placebo followed by 2 weeks of estradiol plus progesterone 200mg (for endometrial safety) on vascular endothelial function and immune-mediated inflammation versus placebo. Patches will be applied by the participant to the lower abdomen twice weekly, alternating sides.

The investigators will be using non-invasive tests to measure vascular function to measures reactive hyperemic index (RHI) using peripheral arterial tonometry (PAT)

02

Conditions studied

  • Estrogen Deficiency
  • Cardiovascular Disease (CVD)
  • Functional Hypothalamic Amenorrhea
  • Endothelial Dysfunction

Keywords

  • estrogen
  • premenopause
  • menopause
  • amenorrhea
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's enrollment of 29 is below the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Cedars-Sinai Medical Center is the lead sponsor of 457 studies on the registry; 108 are open to participants now.

Of its 65 completed or terminated interventional studies of FDA-regulated products, 49 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For premenopausal Hypo E and normal control women, inclusions include:

  • Premenopausal currently not on hormone therapy,
  • English speaking (for the purposes of complete psychosocial assessment)
  • able to give
  • a gynecological age (age since menarche) > 10 and \< 25 years, and chronological age > 18 years
  • Within 90-110% of ideal body weight as determined by the 1983 Metropolitan Height and weight table for women
  • All participants with hypothalamic amenorrhea will be diagnosed based on exclusion of other etiologies for their amenorrhea, including pregnancy, thyroid dysfunction, hyperprolactinemia, premature ovarian insufficiency, and polycystic ovary disease

For recently menopausal women inclusions include:

  • Follicle stimulating hormones (FSH) >30 and 12 months of amenorrhea, within 3 years of final menstrual period with natural menopausal not on hormone therapy
  • English speaking
  • Able to give informed consent
  • Within 90-110% of ideal body weight

Exclusion criteria

Exclusion Criteria:

For premenopausal Hypo E and normal control women exclusions include:

  • Smoking
  • Hypertension
  • Hyperlipidemia
  • Diabetes
  • Medications including psychotropic or illicit drugs, medical, neurological
  • Ophthalmologic disease except acuity problems
  • Major Axis I disorder other than depression
  • Pregnancy in the last 12 months and/or lactating in the last 6 months
  • Current use of hormone or any estrogen or progestin therapy

For HypoE women, exclusion criteria include:

  • Allergy to adhesive or tape

For recently menopausal women exclusions also include:

  • Previous or current use of hormone therapy, estrogen or progestin
  • Surgical or chemotherapy induced menopause
  • Premature ovarian failure
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
29 participants (actual)

Study arms

  • Active comparator
    17Beta Estradiol, Progesterone

    17Beta Estradiol (0.1mg/day) , Progesterone (100mg) or Medroxyprogesterone (10mg) for patient with a peanut allergy because progesterone 100mg is a peanut based product

    Drug: 17beta Estradiol · Drug: Progesterone

  • Placebo comparator
    Transdermal Placebo Patch, Placebo Pill

    Placebo Transdermal Patch, Placebo Pill

    Drug: Transdermal placebo patch · Drug: Placebo Pill

Interventions

  • DrugEstradiolStudies of EstradiolEstradiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will use a dose of transdermal estradiol 0.1 mg/day patch for 12 weeks +/- 1week. PAT index vascular measures and serum immune markers will be measured after 6 and 12 weeks +/- 1week on estrogen patches. Patches will be applied by the participant to the lower abdomen twice weekly, alternating sides.

    Also known as: Estradiol Transdermal Patch, Vivelle-Dot

  • DrugTransdermal placebo patch

    Participants will use a dose of placebo patches for 12 weeks +/- 1 week. Placebos will be applied by the participant to the lower abdomen twice weekly, alternating sides.

  • After 12 weeks +/- 1week of transdermal estradiol patch, participants will use estrogen patch plus progesterone for 2 additional weeks +/- 3 days. Progesterone is a peanut based product and for patients with a peanut allergy we will replace this with a synthetic progestin at an equivalent dose, medroxyprogesterone 10mg.

    Also known as: Prometrium

  • DrugPlacebo Pill

    After 12 weeks +/- 1week of transdermal placebo patch, participants will use placebo patch plus placebo pill for 2 additional weeks +/- 3 days.

    Also known as: Placebo Oral Pill

06

What researchers measure

Primary outcomes

  1. Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry

    Change in PAT measured as reactive hyperemia index (RHI) from baseline to week 12 on treatment or placebo. Reactive hyperemia index (RHI) is the post-to-pre occlusion PAT signal ratio in the occluded arm, relative to the same ratio in the control arm, corrected for baseline vascular tone of the occluded arm calculated by taking the ratio of the pulse amplitude during the hyperemic phase (after a period of blood flow occlusion) to the baseline pulse amplitude. The values below \<1.67 are abnormal and suggest impaired endothelial function or endothelial dysfunction.

    Time frame: Baseline, week 12 on trial

Secondary outcomes

  1. Serum Inflammatory Markers

    Change in serum cortisol from baseline to week 12 on treatment or placebo

    Time frame: Change in serum cortisol from baseline to week 12 on treatment or placebo

  2. Serum Estradiol Levels

    Week 12 serum estradiol levels

    Time frame: Serum estradiol levels after 12 week of treatment vs placebo

  3. Quality of Life (Questionnaire)

    Short-Form Health Survey 12 (SF-12) was reported as the mental component score (MCS) and physical component score (PCS). Each scale ranges from 0 to 100. For both PCS and MCS, higher values represent better outcomes, indicating superior physical or mental health, respectively. Lower scores suggest poorer outcomes in the respective domains. Scores above 50 for either PCS or MCS are generally considered above the population average for health-related quality of life, as the scales are often normed to a mean of 50 with a standard deviation of 10 in general population studies. Scores below 50 suggest below-average physical or mental health, with the degree of deviation providing further insight into the severity of physical or mental health challenges.

    Time frame: Change in quality of life scores after 12 week of treatment vs placebo

  4. Depression

    Patient Health Questionnaire (PHQ-9) total score ranges from 0 to 27. Each item is scored on a scale of 0 (not at all) to 3 (nearly every day), with higher scores indicating greater severity of depressive symptoms. Interpretation of Scores: * 0-4: Minimal or no depression * 5-9: Mild depression * 10-14: Moderate depression * 15-19: Moderately severe depression * 20-27: Severe depression

    Time frame: Change in PHQ-9 Scores after 12 week of treatment vs placebo

  5. Change in Insomnia Severity Index After 12 Week of Treatment vs Placebo

    Change in Insomnia Severity Index after 12 week of treatment vs placebo. Insomnia Severity Index (ISI) total score ranges from 0 to 28.

    Time frame: Insomnia score after 12 week of treatment vs placebo

  6. Anxiety

    Overall Anxiety Severity and Impairment Scale (OASIS) total score ranges from 0 to 20, with each of the 5 items scored on a scale of 0 (no anxiety or impairment) to 4 (extreme anxiety or impairment). Higher scores indicate greater severity and functional impairment related to anxiety. The OASIS scores can be categorized as follows: * 0-4: Minimal or no anxiety * 5-9: Mild anxiety * 10-14: Moderate anxiety with some functional impairment * 15-20: Severe anxiety with significant functional impairment.

    Time frame: Change in Anxiety Scores after 12 week of treatment vs placebo

  7. Stress

    Cohen Perceived Stress Scale (PSS) ranges from 0 to 40, with each of the 10 items scored on a scale of 0 (never) to 4 (very often). Higher scores reflect higher levels of perceived stress. The PSS scores can be categorized as follows: * 0-13: Low perceived stress * 14-26: Moderate perceived stress * 27-40: High perceived stress

    Time frame: Change in stress scores after 12 week of treatment vs placebo

  8. Change in Serum Estradiol Levels

    Change from Baseline to week 12 serum estradiol levels

    Time frame: change in estradiol after 12 week of treatment vs placebo

  9. Serum Inflammatory Markers

    Change in serum hsCRP from baseline to week 12 on treatment or placebo

    Time frame: Change in serum hsCRP from baseline to week 12 on treatment or placebo

07

Results

Posted Feb 24, 2025

Participant flow

Participant flow — Overall Study
Milestone17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo Pill
Started1415
Completed1212
Not completed23

Outcome measures

PrimaryRate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry

Change in PAT measured as reactive hyperemia index (RHI) from baseline to week 12 on treatment or placebo. Reactive hyperemia index (RHI) is the post-to-pre occlusion PAT signal ratio in the occluded arm, relative to the same ratio in the control arm, corrected for baseline vascular tone of the occluded arm calculated by taking the ratio of the pulse amplitude during the hyperemic phase (after a period of blood flow occlusion) to the baseline pulse amplitude. The values below \<1.67 are abnormal and suggest impaired endothelial function or endothelial dysfunction.

Time frame:
Baseline, week 12 on trial
Reported as:
Mean · change of RHI
Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry
change of RHI17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo Pill
Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry0.20 ± 0.520.25 ± 0.64
SecondarySerum Inflammatory Markers

Change in serum cortisol from baseline to week 12 on treatment or placebo

Time frame:
Change in serum cortisol from baseline to week 12 on treatment or placebo
Reported as:
Median · µg/dL
Serum Inflammatory Markers
µg/dL17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo Pill
Serum Inflammatory Markers-0.4 (-4.57 to 1.70)3.1 (0.2 to 5.96)
SecondarySerum Estradiol Levels

Week 12 serum estradiol levels

Time frame:
Serum estradiol levels after 12 week of treatment vs placebo
Reported as:
Median · pg/mL
Serum Estradiol Levels
pg/mL17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo Pill
Serum Estradiol Levels108.0 (85.8 to 165.0)36.5 (16.7 to 51.2)
SecondaryQuality of Life (Questionnaire)

Short-Form Health Survey 12 (SF-12) was reported as the mental component score (MCS) and physical component score (PCS). Each scale ranges from 0 to 100. For both PCS and MCS, higher values represent better outcomes, indicating superior physical or mental health, respectively. Lower scores suggest poorer outcomes in the respective domains. Scores above 50 for either PCS or MCS are generally considered above the population average for health-related quality of life, as the scales are often normed to a mean of 50 with a standard deviation of 10 in general population studies. Scores below 50 suggest below-average physical or mental health, with the degree of deviation providing further insight into the severity of physical or mental health challenges.

Time frame:
Change in quality of life scores after 12 week of treatment vs placebo
Reported as:
Mean · score on a scale
Quality of Life (Questionnaire)
score on a scale17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo Pill
SF12-PCS2.14 ± 7.97-0.45 ± 4.44
SF12-MCS1.83 ± 11.662.69 ± 5.99
SecondaryDepression

Patient Health Questionnaire (PHQ-9) total score ranges from 0 to 27. Each item is scored on a scale of 0 (not at all) to 3 (nearly every day), with higher scores indicating greater severity of depressive symptoms. Interpretation of Scores: * 0-4: Minimal or no depression * 5-9: Mild depression * 10-14: Moderate depression * 15-19: Moderately severe depression * 20-27: Severe depression

Time frame:
Change in PHQ-9 Scores after 12 week of treatment vs placebo
Reported as:
Mean · score on a scale
Depression
score on a scale17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo Pill
Depression-0.67 ± 3.52-0.08 ± 2.09
SecondaryChange in Insomnia Severity Index After 12 Week of Treatment vs Placebo

Change in Insomnia Severity Index after 12 week of treatment vs placebo. Insomnia Severity Index (ISI) total score ranges from 0 to 28.

Time frame:
Insomnia score after 12 week of treatment vs placebo
Reported as:
Mean · score on a scale
Change in Insomnia Severity Index After 12 Week of Treatment vs Placebo
score on a scale17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo Pill
Change in Insomnia Severity Index After 12 Week of Treatment vs Placebo8.0 ± 5.73.9 ± 4.0
SecondaryAnxiety

Overall Anxiety Severity and Impairment Scale (OASIS) total score ranges from 0 to 20, with each of the 5 items scored on a scale of 0 (no anxiety or impairment) to 4 (extreme anxiety or impairment). Higher scores indicate greater severity and functional impairment related to anxiety. The OASIS scores can be categorized as follows: * 0-4: Minimal or no anxiety * 5-9: Mild anxiety * 10-14: Moderate anxiety with some functional impairment * 15-20: Severe anxiety with significant functional impairment.

Time frame:
Change in Anxiety Scores after 12 week of treatment vs placebo
Reported as:
Mean · score on a scale
Anxiety
score on a scale17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo Pill
Anxiety-0.31 ± 3.3-0.54 ± 2.07
SecondaryStress

Cohen Perceived Stress Scale (PSS) ranges from 0 to 40, with each of the 10 items scored on a scale of 0 (never) to 4 (very often). Higher scores reflect higher levels of perceived stress. The PSS scores can be categorized as follows: * 0-13: Low perceived stress * 14-26: Moderate perceived stress * 27-40: High perceived stress

Time frame:
Change in stress scores after 12 week of treatment vs placebo
Reported as:
Mean · score on a scale
Stress
score on a scale17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo Pill
Stress-0.49 ± 3.69-0.46 ± 3.41
SecondaryChange in Serum Estradiol Levels

Change from Baseline to week 12 serum estradiol levels

Time frame:
change in estradiol after 12 week of treatment vs placebo
Reported as:
Median · pg/mL
Change in Serum Estradiol Levels
pg/mL17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo Pill
Change in Serum Estradiol Levels84 (44.3 to 144.8)-4.7 (-14.6 to 4.25)
SecondarySerum Inflammatory Markers

Change in serum hsCRP from baseline to week 12 on treatment or placebo

Time frame:
Change in serum hsCRP from baseline to week 12 on treatment or placebo
Reported as:
Median · mg/L
Serum Inflammatory Markers
mg/L17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo Pill
Serum Inflammatory Markers0.0857 (0.017 to 0.174)0.0322 (-0.00021 to 0.172)

Adverse events

Collected over For the length of the study enrollment, 14 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
17Beta Estradiol, Progesterone0/14 (0%)0/14 (0%)0/14 (0%)
Transdermal Placebo Patch, Placebo Pill0/15 (0%)0/15 (0%)0/15 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo PillTotal
Mean27 ± 6.725.1 ± 6.126.0 ± 6.3
Sex/Gender, Customized
Sex/Gender, Customized(Participants)17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo PillTotal
Female141529
Race (NIH/OMB)
Race (NIH/OMB)(Participants)17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo PillTotal
American Indian or Alaska Native000
Asian325
Native Hawaiian or Other Pacific Islander000
Black or African American000
White10818
More than one race156
Unknown or Not Reported000
BMI
BMI(kg/m^2)17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo PillTotal
Mean21.7 ± 3.721.4 ± 3.121.5 ± 3.3
Waist
Waist(inches)17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo PillTotal
Mean27.1 ± 2.127.1 ± 3.727.1 ± 2.99
Hip
Hip(inches)17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo PillTotal
Mean34.0 ± 2.134.4 ± 3.734.2 ± 3.0
Age at Menarche
Age at Menarche(years)17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo PillTotal
Mean13.1 ± 1.812.9 ± 1.412.96 ± 1.6
Serum Estradiol
Serum Estradiol(pg/mL)17Beta Estradiol, ProgesteroneTransdermal Placebo Patch, Placebo PillTotal
Median24 (12 to 42)30 (26 to 38)25 (18.5 to 35)
08

Study locations

1 site
  • Cedars-Sinai Barbra Streisand Women's Heart Center
    Los Angeles, California 90048, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Feb 2023, 73 months.

Results were first posted in Feb 2025, 2 years after primary completion. A results delay was requested in Jan 2024.

Of 60 non-industry phase 2 interventional studies under Cardiovascular Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 73. This study's 73 months is above that.

Counting every sponsor, half of 84 studies reached it within 28 months; a quarter within 16 and three quarters within 61.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2016
First posted
Jan 12, 2017
StartActual
Jan 1, 2017
Primary completionActual
Feb 1, 2023
CompletionActual
Feb 1, 2023
Results delay requested
Jan 24, 2024
Results first posted
Feb 24, 2025
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03018366
Responsible party
Chrisandra Shufelt (Professor and Chair, Division of General Internal Medicine, Mayo Clinic) — Principal investigator
First posted
Jan 12, 2017
Start date
Jan 1, 2017
Primary completion
Feb 1, 2023
Completion
Feb 1, 2023
Results posted
Feb 24, 2025
Last update
Mar 13, 2025

Study contacts

Chrisandra Shufelt, MD
principal investigator · Cedars-Sinai Medical Center
Noel Bairey-Merz, MD
study director · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Progesterone

Start the discussion